cbdMD Acquires Substantially All Assets of Bluebird Botanicals

January 29, 2026

cbdMD, Inc. (NYSE American: YCBD) acquired substantially all assets of Bluebird Botanicals in early January 2026 to integrate Bluebird's regulatory science, safety and IP assets into cbdMD's clinical and toxicology platform. The deal strengthens cbdMD's regulatory-compliance and GRAS capabilities for both broad-spectrum and full-spectrum cannabinoid formulations and is expected to contribute to revenue growth and expanded product safety dossiers.

Buyers
cbdMD, Inc.
Targets
Bluebird Botanicals
Location
Colorado, United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.